Sellas Life Sciences Group Inc
(SLS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2009 | 03-2009 | 12-2008 | 09-2008 | 06-2008 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4,360 | 7,170 | 9,850 | 3,660 | 9,020 |
| Marketable Securities | 0 | 0 | 0 | 9,010 | 6,050 |
| Other current assets | 330 | 390 | 70 | 330 | 360 |
| TOTAL | $4,690 | $7,560 | $9,920 | $13,000 | $15,430 |
| Non-Current Assets | |||||
| PPE Net | N/A | N/A | 570 | N/A | N/A |
| Other Non-Current Assets | 10 | 10 | 10 | 10 | 10 |
| TOTAL | $10 | $10 | $580 | $10 | $10 |
| Total Assets | $5,100 | $7,960 | $10,350 | $13,370 | $15,840 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 580 | 400 | 390 | 260 | 470 |
| Accrued Expenses | 1,270 | 1,060 | 970 | 890 | 1,030 |
| TOTAL | $1,860 | $1,490 | $1,380 | $1,180 | $1,520 |
| Non-Current Liabilities | |||||
| TOTAL | $10 | $N/A | $4 | $9 | $10 |
| Total Liabilities | $1,870 | $1,490 | $1,390 | $1,180 | $1,530 |
| Shareholders' Equity | |||||
| Common Shares | 1 | 1 | 1 | 1 | 1 |
| Retained earnings | -34,610 | -29,530 | -25,360 | -21,360 | -17,950 |
| Other shareholders' equity | -1 | -1 | -11 | -1 | -11 |
| TOTAL | $3,220 | $6,470 | $8,960 | $12,190 | $14,300 |
| Total Liabilities And Equity | $5,090 | $7,960 | $10,350 | $13,370 | $15,830 |